The main and secondary endpoints of the trial reached in Phase 3 clinical trials of the double inhibitor bimekizumab

today, UCB (UCB)company(http:// announcedthat its target of IL-17A and IL-17F, a dual inhibitor bimekizumab, has reached all major and minor ends of the trial in the phase 3 clinicaltrial(http://in adult patients with severe chronic plaque psoriasis in the treatment of severe chronic plaque psoriaAbout bimekizumabBimekizumab is a universal humanized monoclonal antibody that is powerful and specific and neutralises IL-17A and IL-17FTHE IL-23/IL-17 SIGNAL INGENUOUS PATHWAY IS THE STAR SIGNAL INGLE THAT HAS SPAWNED SEVERAL HEAVY-
NEW DRUGS
(HTTP://WWW.CHEMDRUG.COM/)
Unlike theof thedrug(http:// currently on the market, bimekizumab can simultaneously target THE IL-17A and IL-17F signaling pathways associated with multiple inflammatory reactions, while inhibiting the effects of both cytokines so that bimekizumab may be better anti-inflammatoryPreviously, preclinical studies have shown that simultaneously intsofaring IL-17A and IL-17F can reduce the appearance of skin inflammation, and the efficacy is better than the effect of inhibiting IL-17A aloneBimekizumab is also used in clinical trials to treat patients with psoriasis arthritis (PsA), strong spinal itisis (AS) and non-radioactive axial spinal arthritis (nr-axSpA)A total of 570 patients with plaque-type psoriasis participated in a phase 3 clinical study in the randomized, double-blind, placebo and active control groupThe study was designed to compare the efficacy and safety of bimekizumab compared to another listed IL-12/IL-23 inhibitor, ustekinumab, in the treatment of patients with severe plaque-type psoriasisThe results show that bimekizumab reached the main end of the experimentAfter 16 weeks of treatment, the proportion of patients treated with bimekizumab with a ratio of more than 90% decreased in area and severe index scores decreased by more than 90% (PASI 90), and the proportion of patients with complete or near elimination of skin symptoms (PGA score 0 or 1) was significantly higher than in the active control groupThe proportion of patients with PASI 100 and PGA 0 scores in the Bimekizumab treatment group was also significantly higher than in the placebo group, reaching critical secondary endpoints in the trial